摘要
目的建立肿瘤患者应用重组人粒细胞集落刺激因子(rhG-CSF)评价标准,评估rhG-CSF临床使用的合理性。方法以rhG-CSF药品说明书、中国临床肿瘤学会(CSCO)、美国国立综合癌症网络(NCCN)等发布的相关药物指南或专家共识为依据,制定肿瘤患者应用rhG-CSF评价标准,对2018年蚌埠市第三人民医院50例肿瘤患者使用rhG-CSF的归档病历采用加权TOPSIS法进行分析评价。结果rhG-CSF的不合理应用主要集中在给药途径未首选皮下注射、给药剂量不准确和用药疗程不足等。50例病例中相对接近度(Ci)≥80%的有3例(6%),60%≤Ci<80%的有33例(66%),40%≤Ci<60%的有14例(28%)。结论基于加权TOPSIS法的rhG-CSF合理性评价发现,该院肿瘤患者应用rhG-CSF基本合理,但仍存在给药途径、给药剂量和用药疗程不合理等方面问题。
AIM To establish the evaluation criteria for the use of recombinant human granulocyte colony-stimulating factor(rhG-CSF)in tumor patients,and to evaluate the rationality of clinical practice of rhG-CSF.METHODS The rhG-CSF evaluation criteria for tumor patients was established based on the drug label,relevant drug guidelines or expert consensus issued by the Chinese Society of Clinical Oncology(CSCO)and the National Comprehensive Cancer Network(NCCN).Fifty cases of rhG-CSF archived medical records in the Third People's Hospital of Bengbu in 2018 were analyzed and evaluated by weighted TOPSIS method.RESULTS The unreasonable application of rhG-CSF mainly focused on the subcutaneous injection was not preferred,the inaccurate dosage and the insufficiency of medication,etc.Among the 50 cases,3 cases(6%)had relative proximity(Ci)≥80%,33 cases(66%)had 60%≤Ci<80%,and 14 cases(28%)had 40%≤Ci<60%.CONCLUSION The application of rhG-CSF for tumor patients in this hospital is basically reasonable according to the weighted TOPSIS method.However,there are still some problems,mainly in terms of unreasonable route,dosage and treatment course.
作者
汪龙
宋佳伟
江洁美
王慕华
王莉
钟春生
WANG Long;SONG Jia-wei;JIANG Jie-mei;WANG Mu-hua;WANG Li;ZHONG Chunsheng(Department of Pharmacy,the Third People's Hospital of Bengbu,Bengbu ANHUI 233099,China;Department of Oncology,the Third People's Hospital of Bengbu,Bengbu ANHUI 233099,China;Department of Pharmacy,People's Hospital of Bozhou,Bozhou ANHUI 236800,China;Department of Pharmacy,the First Affiliated Hospital of Anhui Medical University,Hefei ANHUI 230022,China;Department of Pharmacy,the First Affiliated Hospital of Bengbu Medical College,Bengbu ANHUI 233004,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2019年第10期630-634,共5页
Chinese Journal of New Drugs and Clinical Remedies
